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Abstract 
Peroxisomes are eukaryotic organelles that function in numerous metabolic pathways and defects in 
peroxisome function can cause serious developmental brain disorders such as adrenoleukodystrophy 
(ALD). Peroxisomal membrane proteins (PMPs) play a crucial role in regulating peroxisome function. 
Therefore, PMP homeostasis is vital for peroxisome function. Recently, we established that certain PMPs 
are degraded by the Ubiquitin Proteasome System yet little is known about how faulty/non-functional 
PMPs undergo quality control. Here we have investigated the degradation of Pxa1p, a fatty acid transporter 
in the yeast Saccharomyces cerevisiae. Pxa1p is a homologue of the human protein ALDP and mutations in 
ALDP result in the severe disorder ALD. By introducing two corresponding ALDP mutations into Pxa1p 
(Pxa1MUT), fused to mGFP, we show that Pxa1MUT-mGFP is rapidly degraded from peroxisomes in a 
proteasome-dependent manner, while wild type Pxa1-mGFP remains relatively stable. Furthermore, we 
identify a role for the ubiquitin ligase Ufd4p in Pxa1MUT-mGFP degradation. Finally, we establish that 
inhibiting Pxa1MUT-mGFP degradation results in a partial rescue of Pxa1p activity in cells. Together, our 
data demonstrate that faulty PMPs can undergo proteasome-dependent quality control. Furthermore, our 
observations may provide new insights into the role of ALDP degradation in ALD. 
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Introduction 
Peroxisomes are eukaryotic organelles that encompass a protein-rich matrix bound by a single membrane. 
Their morphology, abundance and function depends on species and developmental stage [1]. Some well-
known peroxisomal functions include fatty acid oxidation and hydrogen peroxide detoxification, but many 
more exist [2]. Their importance in human health is underlined by the severe diseases such as 
adrenoleukodystrophy (ALD) caused by defects in peroxisome function [3].  
Peroxisome function is largely determined by peroxisomal protein content. Most peroxisomal 
membrane proteins (PMPs) are synthesized in the cytosol and targeted directly to peroxisomes [4] although 
a subset of PMPs may be delivered to peroxisomes via the endoplasmic reticulum [5]. PMPs regulate many 
aspects of peroxisome biology, including peroxisomal protein import [6], peroxisome numbers [7] and 
small molecule transport into peroxisomes [8]. For peroxisome function, PMP homeostasis is vital; this 
includes the regulation of targeting but also protein quality control processes and protein degradation. 
Recently, we demonstrated that the PMPs Pex3p and Pex13p in the yeast Hansenula polymorpha are 
actively down-regulated [9, 10]. Pex3p degradation initiates selective autophagy of peroxisomes while 
Pex13p degradation is linked to peroxisomal matrix protein import. Both Pex3p and Pex13p are degraded 
by the Ubiquitin Proteasome System (UPS) [11]. In this system, ubiquitin (Ub) is activated by a ubiquitin-
activating enzyme (E1), then transferred to the active site cysteine of an ubiquitin-conjugating enzyme (E2) 
and finally, Ub is attached to the substrate with the aid of an ubiquitin ligase (E3) [12-14]. Three classes of 
E3s exist. HECT E3 ligases accept Ub onto an active site cysteine and then transfer Ub to a substrate [15, 
16], whereas RING E3 ligases act as bridge between E2 and substrate, allowing Ub transfer to occur [17, 
18]. The third class of E3 ligase, known as RING-in-between-RING (RBR) E3s, contain a RING domain, 
followed by an RBR domain and finally a RING-like domain [19]. These RBR E3s, like HECT E3s, accept 
Ub from an E2 onto a cysteine in the RING-like domain before transferring it to the substrate [20]. 
The examples of Pex3p and Pex13p demonstrate that targeted down-regulation of PMPs does 
occur. However, because peroxisomes are involved in various oxidative metabolic reactions, they can 
generate large amounts of reactive oxygen species (ROS) such as hydrogen peroxide [21]. Because ROS 
are toxic compounds which cause damage to biomolecules [22], it is highly likely that PMPs residing in the 
ROS rich environment of the peroxisome undergo oxidative damage. Therefore, PMP quality control is 
likely to play a vital role in peroxisome biology yet to date little is known on how misfolded, non-
functional or faulty PMPs are targeted for degradation via quality control. Here we have investigated PMP 
quality control in the yeast Saccharomyces cerevisiae using Pxa1p as substrate. Pxa1p is a half-ABC 
transporter, containing six transmembrane helices and a nucleotide-binding domain (NBD). The hetero-
dimerization of Pxa1p with Pxa2p, another half-ABC transporter, is required for transporting acyl-CoA 
such as Oleoyl-CoA into peroxisomes [23, 24]. Pxa1p is the homologue of human adrenoleukodystrophy 
protein (ALDP) [25]. Mutations in ALDP cause ALD [26] and many ALDP mutants are rapidly degraded, 
likely by the proteasome [27] . This has led to the suggestion that blocking ALDP degradation might 
constitute a feasible therapeutic approach to treat ALD [27, 28]. However, to date little is known about the 
mechanisms underlying ALDP instability or degradation. 
Using a mutant form of Pxa1p (Pxa1MUT) that mimics ALD-causing ALDP mutations, fused to 
mGFP, we show that Pxa1MUT-mGFP is rapidly degraded from peroxisomes. Furthermore, we show that 
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Pxa1MUT-mGFP degradation is dependent on the proteasome while our data also demonstrate a role for the 
E3 ligase Ufd4p in Pxa1MUT-mGFP degradation. Finally, we show that inhibiting Pxa1MUT-GFP 
degradation partially restores Pxa1p function in vivo. Taken together, our study demonstrates that faulty 
PMPs can undergo proteasome-mediated degradation. Furthermore, our observations on Pxa1MUT-mGFP 
degradation may provide new insights into the role of ALDP stability in ALD. 
 
Results  
Pxa1MUT-mGFP undergoes proteasome-mediated degradation from peroxisomes 
Unlike wild-type (WT) ALDP, many mutant versions of ALDP are unstable and are rapidly degraded [29, 
30], suggesting that quality control of faulty peroxisomal fatty acid transporters occurs. To investigate this 
in S. cerevisiae, we chose to study the degradation of the yeast ALDP homologue Pxa1p. For this, we 
selected two ALD causing mutations in ALDP, a commonly occurring glycine to serine substitution at 
position 512 (p.Gly512Ser) together with a lysine to arginine substitution at position 513 (p.Lys513Arg), 
both present in the walker A motif of the NBD (www.adrenoleukodystrophy.info). The p.Gly512Ser 
mutation causes reduced protein stability in vivo [31] although importantly, it does not abolish ATP-
hydrolysis activity in vitro [32]. The p.Lys513Arg mutation also causes protein instability in vivo 
(www.adrenoleukodystrophy.info). The corresponding ALDP mutations (p.Gly650Ser and p.Lys651Arg) 
were both introduced into yeast PXA1. We chose to introduce two mutations to maximize the destabilizing 
effect to Pxa1p. The Gly650Ser/Lys651Arg mutant form of Pxa1p is referred to as Pxa1MUT. We choose to 
fuse Pxa1MUT to mGFP (Pxa1MUT-mGFP), which allowed us to follow Pxa1MUT using both biochemical and 
microscopy based techniques. Furthermore, the DNA encoding for Pxa1MUT-mGFP was integrated into the 
genome of the S. cerevisiae strains used and therefore represents the only copy of PXA1 in the cells.  
Since Pxa1p functions in transporting fatty acyl-CoA, such as Oleoyl-CoA, LQWRSHUR[LVRPHVIRUȕ-
oxidation [23, 24], we performed all our experiments using cells grown on oleate containing media, to 
better understand the turnover of Pxa1MUT-mGFP under conditions when the protein is required. For this 
purpose, S. cerevisiae cells were pre-cultivated on glucose medium and shifted to oleate medium, to induce 
the expression of the proteins required for peroxisomal ȕ-oxidation [33-35]. However, because we 
performed experiments using deletion mutants that are unable to utilize oleate as carbon source (see 
below), we used oleate medium containing 0.1% glucose throughout the study, to allow results to be 
comparable. Therefore unless otherwise stated, oleate medium always contained 0.1% glucose.  
First, we investigated whether Pxa1MUT-mGFP is properly targeted to peroxisomes. For this, we 
used fluorescence microscopy to examine the localization of Pxa1MUT-mGFP in cells grown on oleate. 
Pex3-mKate2 (Figure 1A) or DsRed-SKL (Figure S1A) was used as a marker for peroxisomes. As control, 
we used cells producing an mGFP-tagged version of WT Pxa1p (Pxa1-mGFP). We observed that mGFP 
spots co-localized with mKate2 spots in strains expressing Pxa1-mGFP (Figure 1A, row 4) or Pxa1MUT-
mGFP (Figure 1A, row 6) while line profile data indicate a strong correlation between the normalized 
fluorescent intensity of mGFP and mKate2 (Figure 1A, row 4 and row 6, right), indicating that both Pxa1-
fusions correctly target to peroxisomes. Likewise, mGFP spots co-localized with DsRed spots in cells 
expressing Pxa1MUT-mGFP and DsRed-SKL (Figure S1A), confirming that Pxa1MUT-mGFP correctly 
targets to peroxisomes. We also observed larger, more diffuse spots in both mGFP and mKate2 channels 
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(Figure 1A, red arrows). However, these were also seen in WT cells lacking fluorescent markers (Figure 
1A, row 1) and likely represent auto-fluorescence.  
The mGFP signal in cells expressing Pxa1MUT-mGFP was lower and fewer GFP spots were visible 
compared to those expressing Pxa1-mGFP (Figure 1A, row 6), which is consistent with the reduced protein 
levels of Pxa1MUT-mGFP compared to those of Pxa1-mGFP (Figure 1B, 1C and S1C). Lower protein levels 
could suggest either reduction in protein production or reduced protein stability. To examine the stability of 
Pxa1MUT-mGFP we performed chase analysis using the protein synthesis inhibitor cycloheximide (CHX). 
For this purpose, cells were pre-cultivated on glucose, transferred to oleate containing media (peroxisome 
inducing conditions) and grown for 11 hrs until an OD600 of ~1.5. After 11 hrs of growth in oleate 
containing media, cells were treated with either CHX or DMSO (control), cells were grown further for 6 
hrs (Pxa1-mGFP) or 2hrs (Pxa1MUT-mGFP) on inducing medium and samples were collected for western 
blotting.  
We observed an increase in Pxa1-mGFP and Pxa1MUT-mGFP levels in DMSO-treated cells over 
time (Figure 2A, DMSO), consistent with the observation that Pxa1-mGFP levels continue to increase until 
~36 hrs after transfer of cells to induction medium (Figure S1D). Significantly, Pxa1MUT-mGFP was rapidly 
degraded and displayed a significantly shorter half-life (~15 mins) compared to Pxa1-mGFP (~360 mins or 
6 hrs) (Figure 2A, CHX and S1E) in cells treated with CHX, indicating that the mutations introduced into 
Pxa1p result in protein instability.  
Next, we sought to determine whether Pxa1MUT-mGFP degradation occurs after targeting to 
peroxisomes. For this, we imaged CHX treated WT cells co-expressing Pex3-mKate2 and Pxa1-mGFP or 
Pxa1MUT-mGFP. We observed that the number of mGFP positive spots reduced over time in cells 
expressing Pxa1MUT-mGFP (Figure 2B, right panel) while cells expressing Pxa1-mGFP displayed many 
more mGFP positive spots after 120 mins of CHX treatment (Figure 2B, left panel). The number of mKate2 
spots remained stable after CHX treatment in both strains (Figure 2B). These observations suggest that 
Pxa1MUT-mGFP is degraded from peroxisomes. To validate this further, we quantified mGFP and mKate2 
fluorescence intensities on peroxisomes in our fluorescent images. We observed that, as expected, the 
mKate2 intensity remained stable over time in the two strains (Figure 2C). Likewise, the mGFP intensity 
on peroxisomes in CHX-treated Pxa1-mGFP cells remained stable (Figure 2C, left panel) but decreased 
rapidly in Pxa1MUT-mGFP cells treated with CHX (Figure 2C, right panel). In addition, the mGFP/mKate2 
ratio in CHX treated Pxa1MUT-mGFP cells decreased rapidly over time but remained stable in Pxa1-mGFP 
cells after CHX addition (Figure 2D). The rate of the decrease in mGFP intensity in Pxa1MUT-mGFP cells 
treated with CHX appears different from that obtained using western blotting (Figure 2A), likely due to the 
high background observed in the mGFP channel (Figure 1A, row 1 and 2). Together, these data strongly 
suggest that Pxa1MUT-mGFP is rapidly degraded from peroxisomes.  
Since ALDP mutants are thought to be degraded via the proteasome [30], we first examined 
whether the proteasome has a role in Pxa1MUT-mGFP degradation, through the use of a mixture of the 
proteasome inhibitors MG132 and Bortezomib (Figure 3A and S1F). We assessed Pxa1MUT-mGFP turnover 
in cells lacking Pdr5p (the major drug efflux transporter [36]), to enhance the uptake of inhibitors [37, 38]. 
In addition, we examined Pxa1MUT-mGFP degradation in cells lacking Atg12p (Figure 3B and S1G), which 
is involved in autophagy [39]. From our CHX chase analysis, we observed that Pxa1MUT-mGFP 
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degradation is inhibited in pdr5 cells after the addition of proteasome inhibitors (Figure 3A, CHX+ 
MG132+Bortezomib) compared to non-treated cells (Figure 3A, CHX). These data, together with the 
observation that the deletion of ATG12 had no effect on Pxa1MUT-mGFP turnover (Figure 3B and S1G) 
demonstrates that the proteasome is involved in Pxa1MUT-mGFP degradation. Next, we checked whether 
ubiquitination has a role in Pxa1MUT-mGFP degradation by expressing a mutant form of ubiquitin (UbK48R) 
in Pxa1MUT-mGFP cells, to inhibit poly-ubiquitin chain formation on the substrate and subsequent 
degradation by the proteasome [40]. We observed that Pxa1MUT-mGFP turnover is reduced in cells 
expressing UbK48R, compared to Ub expressing cells (Figure 3C and S1G). However, we were unable to 
detect ubiquitinated Pxa1MUT-mGFP (Figure 3D). Possibly ubiquitinated Pxa1MUT-mGFP is below the level 
of detection because of the high speed by which Pxa1MUT-mGFP is degraded. In summary, these data 
demonstrate that Pxa1MUT-mGFP undergoes rapid, proteasome-mediated degradation from peroxisomes. 
  
Identifying components required for Pxa1-tFT degradation 
To gain the first insights into mechanisms of Pxa1MUT-mGFP quality control, we set out to identify 
components required for Pxa1MUT-mGFP degradation using a tandem fluorescent protein timer (tFT). A tFT 
is a fusion of two fluorescent proteins; the slow maturing mCherry and the rapid maturing sfGFP (Figure 
4A). When tagged to a protein of interest, the mCherry/sfGFP ratio provides information on protein 
stability. tFT fusions undergoing fast turnover are degraded prior to mCherry maturation, resulting in a low 
mCherry/sfGFP ratio, whereas the mCherry/sfGFP ratio increases for proteins with slower turnover [41]. 
Similar to Pxa1MUT-mGFP, Pxa1-tFT levels in cells were much lower compared to Pxa1-mGFP levels 
(Figure 4B) while Pxa1-tFT was rapidly degraded in cells treated with CHX (Figure 4C and S1H). The 
turnover of tFT-tagged Pex11p, a stable PMP [9], was slower in comparison (Figure 4C and S1H). 
Furthermore, the GFP immunoreactive band at around 33kDa observed with samples containing Pxa1-tFT 
(Figure 4B and S1H, marked **) is derived from incomplete tFT processing by the proteasome [42], 
suggesting a role for the proteasome in Pxa1-tFT turnover. From these data, we conclude that, similar to 
Pxa1MUT-mGFP, Pxa1-tFT undergoes proteasome-mediated degradation and for this reason, we did not 
create a Pxa1-tFT fusion containing the Gly650Ser/Lys651Arg mutations.  
Next, we investigated the stability of Pxa1-tFT in a library of 132 strains that lack a protein 
involved in protein degradation or which contained a mutant version of a protein involved in protein 
degradation (in case the deletion was lethal) using a synthetic genetic array [43, 44]. This library represents 
a large fraction of the factors known to have a role in the degradation of proteins in yeast (see Table S2 for 
details on which strains were included in the library). The effect of the mutations on the stability of Pxa1-
tFT was examined using mCherry/sfGFP intensity ratios obtained from whole colonies after one, two and 
three days of growth on oleate/glucose plates. These mCherry/sfGFP ratios were used to calculate a heat 
map of Z-scores (Figure 4D), which depicts the stability of Pxa1-tFT in each strain. A strain displaying 
similar Pxa1-tFT stability as in WT cells would have a Z-score of 0 while strains with enhanced stability 
would exhibit a Z-score >0 (see materials and methods). Mutant strains that displayed an increase in Z-
score >1.0 on two of the three days tested were considered as potential candidates that increased Pxa1-tFT 
stability. Pxa1-tFT stability was increased in cells lacking functional proteasomes (pre2, pre6, rpn10, rpt6-
25 and ubp6 cells) but not in cells lacking Atg12p (Figure 4D), confirming a role for the proteasome in 
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Pxa1-tFT stability. These results demonstrate that our tFT analysis is a valid way to identify factors 
potentially involved in Pxa1MUT-mGFP degradation.  
Pxa1-tFT stability was increased in strains deleted for genes coding for the peroxisomal E2 Pex4p 
or one of the three peroxisomal E3 ligases Pex2p, Pex10p and Pex12p [45] (Figure 4D). Consistent with 
this, Pxa1-tFT protein levels were enhanced in pex2 and pex4 cells (Figure 4E), thereby confirming our tFT 
data. Roles for these proteins in PMP ubiquitination/degradation have already been reported [9, 10, 46], 
suggesting that common mechanisms may govern PMP ubiquitination and degradation. However, Pxa1-tFT 
stability was also enhanced in cells lacking a number of de-ubiquitinating enzymes (DUBs), which could 
suggest a role for these DUBs in the deubiquitination of Pxa1MUT-mGFP prior to proteasomal degradation. 
In addition, cells lacking the E3s Nam7p, Dma2p, Tul1p and Ufd4p, the E3 co-factor proteins Ela1p and 
Skp2p and the ubiquitin-binding protein Dsk2p (Supplementary Table S2), factors not previously 
associated with peroxisomes, also displayed enhanced Pxa1-tFT stability. Overall, our tFT analysis 
identified factors potentially involved in the degradation of faulty Pxa1p. 
 
Components involved in Pxa1-tFT stability play a role in Pxa1MUT-mGFP degradation 
Previously we demonstrated that the peroxisomal ubiquitination machinery is required for the degradation 
of the PMPs Pex3p and Pex13p [9, 10]. Because deletion of PEX4, PEX2, PEX10 or PEX12 results in 
Pxa1-tFT stabilization (Figure 4D and 4E), we were interested to investigate whether they also had a role in 
Pxa1MUT-mGFP degradation. Indeed, Pxa1MUT-mGFP levels were enhanced in cells deleted for PEX2 or 
PEX4 (Figure 5A and S2A) while Pxa1MUT-mGFP turnover was also inhibited in these cells (Figure 5B and 
S2B), validating our tFT data as well as indicating a role for these peroxisomal proteins in Pxa1MUT-mGFP 
degradation. Furthermore, Pxa1MUT-mGFP localised to peroxisomes in these strains (Figure 5C), indicating 
that stabilisation did not arise from mistargeting to other cell compartments. However, because cells 
deleted for PEX2 or PEX4 also lack function l peroxisomes [47], we investigated the impact of peroxisome 
function alone on Pxa1MUT-mGFP turnover by assessing the stability and turnover of Pxa1MUT-mGFP in 
pex5 cells, which also lack functional peroxisomes [48]. Our data demonstrate that Pxa1MUT-mGFP 
degradation was inhibited in pex5 cells (Figure 5A, B and S2B), suggesting that Pxa1MUT-mGFP 
degradation may be linked to peroxisome function. Again, Pxa1MUT-mGFP targeting was not impaired in 
pex5 cells (Figure 5C). We observed that Pex3-mKate2 levels are comparable in WT, pex2, pex4 and pex5 
cells (Figure S2C), suggesting that the effect of these deletion strains is not general for all PMPs. 
Nevertheless, these data indicate that studying Pxa1MUT-mGFP turnover in strains deficient in peroxisome 
function could be challenging because any effects may potentially be indirect.  
Therefore, we turned to investigate the role of candidates identified in our tFT analysis not 
previously associated with peroxisome function, including Ufd4p, Nam7p, Ela1p, Dsk2p, Skp2p, Tul1p 
and Dma2p. Interestingly, we observed that Pxa1MUT-mGFP levels were significantly higher in cells 
lacking Ufd4p (Figure 6A and S2A). Deletion of ELA1, DSK2, SKP2, TUL1 or DMA2 did not impact 
significantly on Pxa1MUT-mGFP levels (Figure 6A and S2A) and were not investigated further. 
Furthermore, Pxa1MUT-mGFP levels were significantly lower in the NAM7 deletion strain compared to the 
WT (Figure 6A and S2A). However, because we were specifically interested in UPS mutants that 
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increased the stability of Pxa1MUT-mGFP, the role of NAM7 in Pxa1MUT-mGFP stability was not 
investigated further. 
Significantly, we observed that ufd4 cells retain the ability to grow on media containing oleate as 
sole carbon source (Figure 6B), indicating that they contain functional peroxisomes and hence that 
Pxa1MUT-mGFP stabilization in this strain does not stem from a deficiency in peroxisome function. Since 
Ufd4p is a cytosolic E3 ligase that regulates the degradation of faulty proteins [49], but it has not been 
linked to peroxisome function, we chose to investigate the role of Ufd4p in Pxa1MUT-mGFP degradation 
further. We performed CHX chase analysis and observed that Pxa1MUT-mGFP degradation is inhibited in 
ufd4 cells compared to WT cells (Figure 6C and S2B). Furthermore, using fluorescence microscopy in 
combination with CHX chase assays, we investigated the localization and turnover of Pxa1MUT-mGFP in 
ufd4 cells. As can be seen in Figure 6D (t=0, left panel), mGFP spots co-localize with mKate2 spots in ufd4 
cells. In addition, line profile data indicate strong correlation between the normalized fluorescent intensity 
of mGFP and mKate2, demonstrating that Pxa1MUT-mGFP is indeed localised to peroxisomes in ufd4 cells 
(Figure 6D). The peroxisomal localisation of Pxa1MUT-mGFP in ufd4 cells was confirmed using DsRed-
SKL as a peroxisomal marker (Figure S1A). Significantly, cells deleted for UFD4 display increased 
numbers of mGFP spots after 120 mins of CHX treatment, compared to the WT strain (Figure 6D, right 
panel; t=120 mins). Furthermore, mGFP spots in ufd4 cells co-localize with mKate2 spots after 120 mins of 
CHX treatment (Figure 6D, left panel), demonstrating that Pxa1MUT-mGFP accumulates on peroxisomes in 
these cells. Together, these data establish that the E3 ligase Ufd4p is involved in the proteasome-dependent 
degradation of Pxa1MUT-mGFP. 
 
Inhibiting Pxa1MUT-mGFP degradation enhances SHUR[LVRPDOȕ-oxidation 
Around 70% of the mutant forms of ALDP are unstable and are degraded [30, 50]. However, many of these 
mutants retain a certain level of functionality [32]. This has led to the hypothesis that blocking ALDP 
degradation could enhance ALDP activity in cells and be beneficial for ALD patients [27-29]. Our data 
clearly indicate that Pxa1MUT-mGFP builds up at peroxisomes when its degradation is inhibited in ufd4 
cells. Hence, we reasoned that we could use our experimental setup as proof of principle and measured the 
capacity of WT and ufd4 cells expressing Pxa1-mGFP or Pxa1MUT-P*)3WRSHUIRUPȕ-oxidation (Figure 
7A). Pxa1MUT-mGFP in WT cells displayed reduced activity in comparison to Pxa1-mGFP (Figure 7A) 
although higher than pxa1 cells, indicating that importantly, Pxa1MUT-mGFP retains a degree of 
functionality. Significantly, ufd4 cells expressing Pxa1MUT-mGFP exhibited an LQFUHDVH LQ ȕ-oxidation 
activity of around 15% compared to the activity of WT.Pxa1MUT-mGFP cells (Figure 7A). We also 
REVHUYHGWKDWȕ-oxidation appeared enhanced in ufd4 cells expressing Pxa1-mGFP compared to WT cells, 
although statistical analysis suggested that this increase was not significant (Figure 7A). To investigate 
further, we determined the levels of Pxa1-mGFP in WT and ufd4 cells expressing Pxa1-mGFP (Figure 7B), 
observing that these levels were indeed increased in ufd4 cells. Significantly, Pex14p levels were not 
affected by ufd4 deletion (Figure 7B), indicating that the effect is likely to be specific for Pxa1-mGFP. 
Overall, our results provide proof of principle that blocking Pxa1MUT-mGFP degradation can 
partially restore Pxa1MUT-mGFP function in cells, supporting the view that inhibiting ALDP degradation 
may be a promising therapeutic avenue to explore to target ALD.  
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Discussion 
Here we have demonstrated that a faulty version of the peroxisomal fatty acid transporter Pxa1p is targeted 
for proteasome-dependent degradation. Pxa1MUT-mGFP, our chosen substrate, is rapidly degraded from 
peroxisomes. An important question remains how Pxa1MUT-mGFP is recognized for degradation? The 
mutations introduced into Pxa1p (Gly650Ser/Lys651Arg) are present in the conserved walker A motif of 
the NBD [51]. Mutation of either these conserved lysine or glycine residues compromises both the ATP 
hydrolysis and substrate translocation activity of ABC transporters [52-54], including ALDP [32]. Hence, 
the substitutions we introduced into Pxa1MUT-mGFP likely reduce ATP hydrolysis and hence transport 
activity, which in turn could allow Pxa1MUT-mGFP to be recognized for degradation. However, Pxa1p 
forms a heterodimer with Pxa2p and deletion of PXA2 decreases the stability of Pxa1p [55], indicating that 
Pxa2p binding is required for Pxa1p stability. Therefore, it is equally possible that the substitutions in 
Pxa1MUT-mGFP inhibit binding to Pxa2p, which in turn allows Pxa1MUT-mGFP to be recognized for 
degradation. Interestingly, Byeon et al. reported that mutating the walker A lysine in muscle adenylate 
kinase results in a conformational change in the NBD [52] while recent work on the bacterial transporter 
MJ0796 demonstrated that walker A lysine mutations impact on both ATP hydrolysis and homo-
dimerization [54]. Hence, we speculate that the introduced mutations in Pxa1MUT-mGFP result in a 
conformational change in Pxa1p, which could allow the protein to be recognized for degradation. 
Identifying which factors are involved in the recognition of faulty peroxisomal fatty acid transporters will 
provide valuable insights into the mechanisms underlying their degradation.  
Our data show that the addition of proteasome inhibitors significantly reduce Pxa1MUT-mGFP 
turnover, demonstrating a role for the proteasome in Pxa1MUT-mGFP degradation (Figure 3A). While the 
data on the ubiquitin mutant (UbK48) suggests that ubiquitination is involved in Pxa1MUT-mGFP degradation 
(Figure 3C), our attempts to detect ubiquitinated forms of Pxa1MUT-mGFP proved unsuccessful (Figure 
3D). Notably, ubiquitinated forms of ALDP carrying the R617H or H667D mutations could also not be 
detected [30], even though these mutants were likely degraded by the proteasome. There could be two 
possible explanations for his: Pxa1MUT-mGFP is ubiquitinated but that the ubiquitinated form of Pxa1MUT-
mGFP is below the limit of detection, or that the ubiquitination of another protein could facilitate the 
degradation of Pxa1MUT-mGFP. The latter mode of degradation has been proposed for several substrates of 
the proteasome. Dang et al., reported that instead of A3G, its binding partner viral infectivity factor (Vif) 
undergoes poly-ubiquitination and this could be critical for A3G proteasomal degradation [56], proposing 
that poly-ubiquitinated Vif might act as an adaptor protein to bring A3G to the proteasome for degradation 
[57]. Another protein that may be degraded via a similar mechanism is the retinoblastoma tumour 
suppressor protein (Rb) [58]. Rb is thought to be targeted for proteasomal degradation by the ubiquitination 
of its binding partner, human papillomavirus protein E7 [58, 59]. Pxa2p forms a heterodimer with Pxa1p 
[23, 24], but we do not suspect that Pxa2p ubiquitination is required for Pxa1MUT-mGFP degradation 
because loss of Pxa2p does not inhibit Pxa1p degradation but instead decreases the stability of Pxa1p [55]. 
Clearly further work is required to investigate how ubiquitin contributes to the proteasome-mediated 
degradation of Pxa1MUT-mGFP. 
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Based on the results of our tFT screening, several proteins not previously associated with 
peroxisomal function were identified that could play a role in Pxa1-tFT stability (Figure 4C). Of these, only 
loss of Ufd4p, a cytosolic E3 ligase involved in the degradation of faulty proteins [49], significantly 
increased the stability of Pxa1MUT-mGFP (Figure 6A), indicating that Ufd4p is involved in Pxa1MUT-mGFP 
degradation. Although future work needs to investigate the mechanisms by which Ufd4p controls Pxa1MUT-
mGFP degradation, we consider it significant that a cytosolic E3 ligase could regulate the turnover of a 
faulty PMP because this indicates that general cellular quality control pathways can facilitate the 
degradation of faulty PMPs. While the data we present here concern the degradation of a mutant form of 
Pxa1p, we consider it unlikely that the sole purpose of PMP quality control is the degradation of mutant 
PMPs; we consider it more likely that damaged PMPs undergo quality control. As previously mentioned, 
the ROS rich environment of the peroxisome could result in the oxidative damage of proteins, which could 
suggest that damaged Pxa1p undergoes PMP quality control. In line with this, although Pxa1-mGFP is 
much more stable than Pxa1MUT-mGFP in our CHX experiments, degradation of Pxa1-mGFP does occur 
(Figure 2A) while Pxa1-mGFP levels are higher in ufd4 cells compared to WT cells (Figure 7B). Therefore, 
it is plausible that Pxa1MUT-mGFP is targeted for degradation via quality control mechanisms that usually 
acts upon damaged Pxa1p because Pxa1MUT-mGFP is impaired in function. 
Deletion of UFD4 does not fully inhibit the degradation of Pxa1MUT-mGFP. Similarly, Pxa1MUT-
mGFP degradation appears only partly reduced in cells lacking the peroxisomal E3 ligase Pex2p. This 
could suggest that two pathways target Pxa1MUT-mGFP for degradation, one requiring Ufd4p and the other 
involving Pex2p or perhaps that Pex2p and Ufd4p collaborate to facilitate Pxa1MUT-mGFP degradation. 
Ufd4p can team up with Ubr1p, a RING E3, to facilitate the degradation of Mgt1p, a DNA repair 
demethylase [60]. However, the impact of peroxisome function on Pxa1MUT-mGFP degradation remains to 
be determined, meaning that further data on the role of Pex2p (and other members of the peroxisomal 
ubiquitination machinery) are required to validate this hypothesis. Nevertheless, a model that depicts Pex2p 
and Ufd4p teaming up to degrade faulty PMPs remains an attractive one. 
Mutations in gene sequences can result in formation of faulty proteins, which could pose serious 
threats to the cell, for two reasons. One reason is the loss of protein activity. However, there is also gain-of-
toxic function that is unrelated to the protein's function and which has become increasingly relevant to 
human disease [61]. Faulty proteins often expose hydrophobic regions normally buried within the core [62] 
that may take part in unwanted protein-protein interactions, resulting in protein aggregation [63]. To 
minimize such harmful effects, cell employs protein quality control systems to remove faulty proteins [64]. 
For instance, mutations at position F508 in Cystic fibrosis transmembrane conductance regulator (CFTR), 
which increase the tendency of CFTR to aggregate but do not inhibit activity completely [65, 66], result in 
rapid protein degraded [67]. However, the rapid degradation of mutant CFTR leaves cells devoid of CFTR 
molecules, eventually resulting in the severe condition cystic fibrosis [68] and several lines of research 
have focused on blocking CFTR degradation as potential treatment for cystic fibrosis [69]. Similarly, many 
ALDP mutant proteins that cause ALD are unstable, leading to the suggestion that blocking ALDP 
degradation could represent a novel treatment for ALD [27]. Indeed, a subset of ALDP mutant proteins in 
patient cells become stable under low-temperature culture conditions and exhibit proper peroxisomal 
localization [27] while they also display increased UHVLGXDOȕ-oxidation activity [28]. Though unstable, a 
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significant proportion of ALDP mutants retain a certain degree of function [27, 32]. In line with this, our 
data demonstrate that Pxa1MUT-P*)3FHOOVGLVSOD\LQFUHDVHGȕ-oxidation compared to pxa1 cells (Figure 
7A), indicating that Pxa1MUT-mGFP is partly functional. Furthermore, stabilizing Pxa1MUT-mGFP, through 
the deletion of UFD4, HQKDQFHVSHUR[LVRPDOȕ-oxidation in cells, which would indeed support the notion 
that blocking ALDP mutant degradation might constitute a feasible therapeutic approach to treat ALD. 
However, Yamada et al. indicated that proteasome inhibitors enhance the stability of certain ALDP mutants 
but did QRWLQFUHDVHSHUR[LVRPDOȕ-oxidation in the corresponding cells [29]. While these results may seem 
contradictory to those reported here, it is important to note that the location where the mutants build up 
upon stabilization is critical in determining whether stabilization will result in enhanced activity. Yamada 
and co-workers did not address this in their study [29] and it is possible that these ALDP mutants are 
stabilized elsewhere in the cell. Hence, further work on the mechanism of ALDP degradation is therefore 
needed to understand at which point blocking ALDP mutant degradation could positively affect ALDP 
activity. Nevertheless, our data demonstrate that UFD4 deletion results in a build-up of Pxa1MUT-mGFP at 
the peroxisomal membrane and significantly, a human homolog of Ufd4p, known as TRIP12 [70], is 
involved in the degradation of a range of different proteins [71-73]. It would therefore be interesting to 
investigate whether TRIP12 has a role in ALDP degradation and if so, whether blocking TRIP12 dependent 
ALDP mutant degradation improves ȕ-oxidation in ALD patients.   
 In summary, we have demonstrated that a faulty peroxisomal fatty acid transporter undergoes 
proteasome-mediated degradation and identify Ufd4p as playing an important role in facilitating this 
degradation. In addition, these results may help to shed new light on the role of ALDP degradation in ALD. 
 
Materials and Methods 
Construction of plasmids and S. cerevisiae strains  
S. cerevisiae transformations were performed with the Lithium acetate method, as described previously 
[74]. S. cerevisiae strains and plasmids used in this study are listed in Table 1 and 2 respectively. The 
primers used in the study are listed in Table S1. Phusion DNA polymerase (Thermo Scientific) was used 
for the amplification of gene fragments.  
The S. cerevisiae WT.Pxa1-mGFP strain was constructed as follows. PCR was performed on 
pHIPZ-mGFP using the Pxa1-mGFP Fw and Pxa1-mGFP Rev primers to amplify the C-terminal region of 
PXA1 together with the Zeocin resistance cassette (bleMX6) and the mGFP coding sequences and the 
obtained PCR fragment was transformed into the yMaM330 strain. The plasmid pGW053 was constructed 
as follows: the genomic region of the PXA1 gene was amplified by PCR using Forward primer VIP1080, 
485 bp upstream of open reading frame and Reverse primer VIP1081, 192 bp downstream of ORF. This 
was inserted into Ycplac111 using gap repair between EcoR1 and HindIII sites, resulting in pGW046. This 
plasmid was used as template for site directed mutagenesis to generate Pxa1 G650S/K651R using VIP672 
and VIP673, producing pGW053. For the construction of S. cerevisiae WT.Pxa1MUT-mGFP, first a 
recombinant plasmid pHIPZ-Pxa1MUT-mGFP was constructed. PCR was performed on pGW053 using 
Pxa1MUT Fw and Pxa1MUT Rev primers to amplify the C-terminal region of PXA1 (carrying the two 
mutations G650S/K651R) and to introduce Pcil and BglII sites. The resulting DNA fragment, digested with 
Pcil and BglII, was cloned into Pcil/ BglII cut pHIPZ-mGFP to generate pHIPZ-Pxa1MUT-mGFP. PCR was 
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then performed on pHIPZ-Pxa1MUT-mGFP using Int_Pxa1MUT Fw and Int_Pxa1MUT Rev to amplify the 
Pxa1MUT-mGFP fragment and the obtained PCR product was then transformed into the yMaM330 strain. 
The obtained PCR fragment was also transformed into pdr5, atg12 and ufd4 strains to pdr5.Pxa1MUT-
mGFP, atg12.Pxa1MUT-mGFP and ufd4.Pxa1MUT-mGFP respectively. The positive transformants of 
WT.Pxa1MUT-mGFP, pdr5.Pxa1MUT-mGFP, atg12.Pxa1MUT-mGFP and ufd4.Pxa1MUT-mGFP were checked 
both by colony PCR and sequencing. In addition, PCR fragment was also transformed into nam7, ela1, 
dsk2, skp2, dma2 and tul1 cells to generate the mutant strains expressing Pxa1MUT-mGFP. 
The S. cerevisiae Pxa1-tFT strain was generated as follows. PCR was performed on pMaM168 to 
amplify C-terminal region of PXA1 and tFT tagging module using primers Pxa1-tFT Fw and Pxa1-tFT Rev. 
The generated PCR product was then transformed into yMaM330. Strains expressing Pex3-mKate2 were 
constructed as follows. Pex3-mKate2 cassette consisting of C-terminal region of PEX3, hygromycin 
resistance gene (hphMX) and mKate2 coding sequences was amplified from pHIPH-Pex14mKate2 using 
primers Pex3-mKate Fw and Pex3-mKate Rev. The generated PCR fragment was transformed into WT, 
WT.Pxa1-mGFP, WT.Pxa1MUT-mGFP and ufd4.Pxa1MUT-mGFP. Furthermore, the PCR fragment was also 
transformed into pex2. Pxa1MUT-mGFP, pex4. Pxa1MUT-mGFP and pex5. Pxa1MUT-mGFP strains, which 
were generated as described below 
S. cerevisiae WT.Pxa1MUT-mGFP and ufd4.Pxa1MUT-mGFP strains expressing DsRed-SKL were 
constructed as follows. First, the PCR cassette (consisting of TEF promoter and DsRed-SKL coding 
sequences) was digested NotI/SalI and cloned into NotI/SalI cut pHIPX7-DsRed-SKL to create pHIPH7-
DsRed-SKL. The PCR cassette containing TDH3 promoter sequence was amplified from pPTDH3-GFP-SKL 
was digested with NotI/BamHI and cloned into NotI/BamHI cut pHIPH7-DsRed-SKL, to create pHIPH8-
DsRed-SKL. The resulting plasmid after linearization with MunI was transformed into WT.Pxa1MUT-mGFP 
and ufd4.Pxa1MUT-mGFP strains to generate WT.Pxa1MUT-mGFP. DsRedSKL and ufd4.Pxa1MUT-mGFP. 
DsRed-SKL respectively. In these strains, the expression of DsRed-SKL was under the control of TDH3 
promoter.  
S. cerevisiae WT.Pxa1MUT-mGFP+MycUb and WT.Pxa1MUT-mGFP+MycUbK48R strains were 
constructed as follows. First, the Yeast episomal plasmids (YEP) expressing MycUb and MycUbK48R from 
the CUP1 promoter were constructed: the CUP1 promoter coding sequence was amplified from pCGCN-
FAA4 using primers CUP1_Fw and CUP1_Rev, digested with NotI/BamHI and cloned into NotI/BamHI 
cut pRDV1 (MycUb) or pRDV2 (MycUbK48R). The resulting vectors were then used to amplify Pcup1-
MycUb and Pcup1-MycUbK48R sequences individually using primers CUP1_Fw and 
MycUb/UbK48R_Rev and these PCR fragments were digested with NotI and SacI and cloned into NotI/ 
SacI cut pRG226 (Addgene, 64529). The YEP-PCUP1-MycUbK48R plasmid was transformed into the 
WT.Pxa1MUT-mGFP strain to generate WT.Pxa1MUT-mGFP+MycUbK48R. The YEP-PCUP1-MycUb plasmid 
was transformed individually into WT.Pxa1MUT-mGFP, pdr5.Pxa1MUT-mGFP and pdr5 strains to generate 
WT.Pxa1MUT-mGFP+MycUb, pdr5.Pxa1MUT-mGFP + MycUb and pdr5 + MycUb respectively. 
 
Construction of S. cerevisiae deletion strains  
The pxa1 deletion strain was constructed by replacing the PXA1 region with the hygromycin resistance 
gene (hphMX). A PCR fragment containing the hygromycin resistance gene and PXA1 flanking regions 
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were amplified from pHIPH-Pex14mKate2 using primers DPxa1_Fw and DPxa1_Rev. The resulting PXA1 
deletion cassette was transformed into yMaM330. For the construction of pex5.Pxa1MUT-mGFP, the PEX5 
deletion cassette (geneticin resistance gene and PEX5 flanking regions) amplified from pFa6AkanMX6 
using primers DPex5_Fw and DPex5_Rev was transformed in WT.Pxa1MUT-mGFP. 
 S. cerevisiae pex2 and pex4 strains expressing Pxa1MUT-mGFP or Pxa1-tFT were constructed as 
follows. The pex2 and pex4 deletion cassettes consisting of geneticin resistance cassette (kanMX) and PEX2 
or PEX4 flanking regions were amplified from pFa6AkanMX6 using DPex2_Fw and DPex2_Rev (for 
PEX2 deletion cassette) and DPex4_Fw and DPex4_Rev (for PEX4 deletion cassette). The obtained 
deletion cassettes were then transformed individually into WT.Pxa1MUT-mGFP and Pxa1-tFT strains to 
generate pex2. Pxa1MUT-mGFP, pex4. Pxa1MUT-mGFP, pex2.Pxa1-tFT and pex4.Pxa1-tFT strains.  
For the construction of atg12.Pxa1-tFT strain, deletion cassette consisting of geneticin resistance 
cassette (kanMX) and ATG12 flanking regions was amplified from pFa6AkanMX6 using primers 
DAtg12_Fw and DAtg12_Rev (for ATG12 deletion cassette). The obtained deletion cassette was then 
transformed into Pxa1-tFT to generate atg12.Pxa1-tFT strain. 
All gene integrations were confirmed by colony PCR using Phire Hot Start II DNA polymerase 
(Thermo Fisher Scientific) and gene deletions were checked by colony PCR as well as southern blotting 
analysis of chromosomal DNA, using the ECL Direct Nucleic Acid Labelling and Detection system 
(Thermo Fisher Scientific), according to the protocol provided by the manufacturer. 
 
Growth conditions 
The Escherichia coli VWUDLQ '+Į ZDV XVHG IRU FORQLQJ SXUSRVHV E. coli cells were grown in LB 
supplemented with 100 ȝJPO $PSLFLOOLQ DW  °C. Yeast transformants were selected on YPD plates 
containing 2% agar and 100 ȝJPO =HRFLQ ,QYLWURJHQ  ȝJPO *HQHWLFLQ ,QYLWURJHQ RU  ȝJPO
Hygromycin (Invitrogen) or on YND plates containing 6.7 g/L yeast nitrogen base without amino acids 
(YNB, Difco), 5g/L D- glucose monohydrate (Sigma-Aldrich), 2% agar and 30 mg/L Leucine, 20 mg/L 
Histidine and 20 mg/L Methionine or 30 mg/L Uracil, when required.  
For all the experiments, yeast cells were initially cultured at 30°C on YM2 medium (6.7 g/L YNB, 
1% casein hydrolysate (Sigma-Aldrich), 60 mg/L uracil, 60 mg/L tryptophan) containing either 2% or 0.3% 
(w/v) glucose. To induce peroxisome proliferation, cells grown on YM2 medium plus 0.3% glucose were 
transferred to YNO-glucose medium (6.7 g/L YNB, 1% casein hydrolysate, 60 mg/L uracil, 60 mg/L 
tryptophan, 0.05% tween, 0.1% oleate and 0.1% glucose). For strains expressing Myc tagged ubiquitin: 
MycUb and MycUbK48R under the control of CUP1 promoter and uracil coding gene, URA3 (Table 1), cells 
were pre-cultured at 30°C on YM2 medium (lacking uracil) plus 0.3% glucose and then grown on YNO-
glucose medium (lacking uracil) to an OD600 of 1.5. To inhibit protein synthesis, cells were treated with 
cycloheximide (CHX, Sigma-Aldrich) to a final concentration of 6 mg/ml. To inhibit proteasome, cells 
were treated with 70 ȝ0 RI 0* Sigma-Aldrich) and 70 ȝ0 RI %RUWH]RPLE Selleckchem).Where 
indicated, an equal amount of DMSO (control for CHX) was added to cells. For spot assays, yeast strains 
were grown overnight on YM2 medium containing 2% glucose and shifted to YM2 medium plus 0.3% 
glucose. After 6h of growth in YM2 plus 0.3 glucose, yeast cells were spotted onto oleate plates containing 
6.7 g/L YNB, 0.1% yeast extract, 0.1% oleate, 0.05% Tween, 2% agar and when required uracil (30 mg/L), 
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leucine (60 mg/L), methionine (20 mg/L) and histidine (20 mg/L) was added. Plates were incubated at 
30°C for 7 days before imaging. 
 
Preparation of yeast TCA lysates 
Cell extracts of TCA-treated cells were prepared for SDS-PAGE as described previously [75]. SDS-PAGE 
and western blotting were performed by established methods. Equal volume of samples were loaded per 
lane and blots were probed with antibodies against mGFP (Santa Cruz Biotech, sc-9996), pyruvate 
carboxylase 1 (Pyc), Pex14p, rabbit polyclonal antisera raised against the Myc tag (Santa Cruz Biotech, sc-
789) or HA tag (Sigma, H6908). Secondary goat anti-rabbit (Thermo Fisher Scientific, 31460) or goat anti-
mouse (Thermo Fisher Scientific, 31430) antibodies conjugated to horseradish peroxidase or alkaline 
phosphatase were used for detection. Pyc was used as a loading control.  
 
Quantification of Western blots 
Western blots were scanned using a densitometer (Bio-Rad, GS-710) and protein levels were quantified 
using Image J software (https://imagej.nih.gov/ij/). The intensity of each band measured was normalized by 
dividing by the intensity of the corresponding Pyc band (loading control). The normalized Pxa1MUT-mGFP 
values were compared to Pxa1-mGFP values, which was set to 1. The levels of Pxa1MUT-mGFP in mutant 
cells are displayed relative to Pxa1MUT-mGFP levels in WT (set to 1). For CHX experiments, the 
normalized values at time point 0 (T0) was set to 1.0 and values obtained after CHX addition at indicated 
time points are displayed as a fraction of T0 values. Standard deviations were calculated using Excel. 
6LJQLILFDQFHZDVGHWHUPLQHGXVLQJWZRWDLOHGVWXGHQW¶VW-test. * represents P-values < 0.05, ** represents P-
values < 0.01, and *** represents P-values < 0.001. The data presented are derived from three independent 
experiments.  
 
tFT screening with UPS deletion library 
Tandem fluorescent protein timers (tFT): mCherry and sfGFP were endogenously tagged to Pxa1 as 
described [76]. By the use of a pinning robot (Singer Instruments), Pxa1-tFT was crossed to UPS deletion 
library or an array of haploid strains consisting of knockout, temperature sensitive (ts) and Decreased 
Abundance by mRNA perturbation (DAmp) alleles of individual components of the Ubiquitin Proteasome 
System (UPS) [44, 77, 78]. In addition, Pxa1-tFT was crossed to a control strain expressing 
kanMX selection marker from the ura3ǻORFXV, referred to as wild-type (WT). Screens were performed in 
1536 format, with four technical replicates of each cross arranged next to each other. The selection of 
diploids, sporulation and the selection of haploids carrying Pxa1-tFT and a genetic perturbation, was 
performed by sequential pinning on appropriate selective media as described [79], followed by seamless 
marker excision [76]. Using an Infinite M1000 Pro plate reader equipped with automatic plate loading 
stacker (Tecan) and custom temperature control chamber, mCherry intensity (587/10 nm excitation, 610/10 
nm emission) and sfGFP intensity (488/10nm excitation, 510/10 nm emission) was measured from colonies 
grown on a modified YNO-glucose medium containing (6.7 g/L YNB, 2g/L amino acid dropout mix (-
LEU), 0.05% tween, 0.1% oleate, 0.1% glucose and 2% agar). First set of measurements were taken after 
24 h of growth and measurements were taken every 24 h until 72 h (3 days). 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 
14 
 
Whole colony fluorescence intensities (mCherry and sfGFP), obtained from UPS mutant crossed to 
Pxa1-tFT, were corrected for auto fluorescence by subtracting the measurements of a corresponding mutant 
crossed to the control strain, yMaM344 (expressing non-fluorescent protein). The median value was 
calculated out of the four technical replicates. The corrected values of mCherry divided by the sfGFP 
values yielded a ratio, representing the stability of Pxa1-tFT in the UPS mutants. Similarly, the 
mCherry/sfGFP ratio of Pxa1-tFT in WT was corrected for auto fluorescence. Using the ratios obtained on 
day one, two and three a Z- score for each day was calculated by the formula. A Z-score indicates how 
many standard deviations a value is from the mean of all values. Z-score can be calculated from the 
formula: Z= (X - ȝı,QWKHIRUPXOD=LVWKH=-score, X is the value of the HOHPHQWȝLVWKHSRSXODWLRQ
PHDQDQGıLVWKHVWDQGDUGGHYLDWLRQ. A negative Z-score indicates that the value of the element is below 
average while positive Z-score indicates the value is above average. To identify UPS mutants which 
potentially increased the stability of Pxa1-tFT, Z-score (Z) was calculated using the formula  
 
Z = mCherry/sfGFP ratio in a UPS mutant (X) ± mean mCherry/sfGFP ratio in WT and UPS mutants (ȝ 
                      Standard deviation of mCherry/sfGFP ratio in WT and UPS mutants (ı) 
 
A strain (UPS mutant) with a Z-score of 0 indicates that Pxa1-tFT stability is similar to the WT as well to 
the population mean (WT and UPS mutants). While, the mutants with Z-score of 1.0 and 2.0 indicates that 
the mCherry/sfGFP ratio in a corresponding mutant is different from the WT and population mean by 1.0 
and 2.0 standard deviations. Hence, mutant stains displaying a Z-score >0 indicate enhanced Pxa1-tFT 
stability. UPS mutants with an increase in Z-score >1.0 on two of the three days tested were considered as 
potential candidates that significantly increased Pxa1-tFT stability. The heat map generated using the Z-
scores (obtained from mCherry/sfGFP ratio of Pxa1-tFT in UPS mutants and the WT) is presented in 
Figure 2D. 
 
Fluorescence microscopy 
All images were captured at room temperature using an inverted microscope (Axio Scope A1, 100×1.30 
NA Plan-Neofluar objective, Carl Zeiss), Micro-Manager software and a digital camera (CoolSNAP HQ2; 
Photometrics). For wide field microscopy, GFP fluorescence was visualized with a 470/440-nm band pass 
excitation filter, a 495-nm dichromatic mirror, and 525/50-nm band pass emission filter. mCherry 
fluorescence was visualized with a 587/25-nm band pass excitation filter, a 605-nm dichromatic mirror, and 
647/70-nm band pass emission filter. 
 For co-localization analysis, cells were pre-grown on YM2 medium containing glucose, transferred to 
YNO-glucose (low fluorescence) medium and grown until an OD600 of 1.5 after which fluorescence 
microscopy images were captured. For CHX chase analysis, cells grown in the same way as indicated 
above were treated with cycloheximide (CHX) and images were taken from cells grown on oleate/glucose 
at indicated time points (mins) after CHX treatment (Figure 2B). The acquired images were processed 
using Image J software (https://imagej.nih.gov/ij/) with optimal settings: mGFP (200, 500), mKate2 (200, 
600) and DsRed (200, 500). For co-localization analysis in WT, pex2, pex4 and pex5 cells expressing 
Pxa1MUT-mGFP and Pex3-mKate2 (Figure 5C), images were processed using optimal settings: mGFP (200, 
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800) and mKate2 (200, 600). For quantifying the co-localization of Pxa1-mGFP or Pxa1MUT-mGFP in cells 
expressing peroxisomal markers (Pex3-mKate2 or DsRed-SKL) (Figure 1, 2, 6 and S1), a line was drawn 
along GFP and mKate2/ DsRed-SKL spots using ImageJ and the intensity was measured. Using this data, 
normalized fluorescent intensity of green and red spots were calculated and plotted against the distance of 
the line (from the beginning to the end). 
For quantification of the Pex3-mKate2 and Pxa1-mGFP or Pxa1MUT-mGFP fluorescence intensities in 
CHX treated cells (Figure 2C), a rectangular area was drawn using ImageJ to envelope the region 
containing the mGFP/mKate2 spot and pixel intensity inside the area was measured. Since the cells 
expressing Pxa1MUT-mGFP contain very few mGFP positive spots at the later time points of CHX 
treatment, the rectangular area selected contained the peroxisomal marker or Pex3-mKate2 spots and the 
corresponding mGFP intensity was measured. The maximum fluorescence intensity of mGFP measured on 
peroxisomes was corrected for the background intensity and a box plot was made using Microsoft Excel. 
The box represents values from the 25 percentile to the 75 percentile; the horizontal line through the box 
represents the median value. Whiskers indicate maximum and minimum values. The mKate2 intensity was 
calculated and displayed in a similar way (Figure 2C). To calculate the mGFP/mKate2 intensity ratio, the 
maximum intensity of Pxa1-mGFP or Pxa1MUT-mGFP, obtained at different time points after CHX 
treatment, was divided by the corresponding maximum intensity of Pex3-mKate2 in each cell. The dataset 
was subjected to the two-tail t-test. * represents P-values < 0.05, ** represents P-values < 0.01 and *** 
represents P-values < 0.001. 
 
Immunoprecipitation assay 
Immunoprecipitation was performed on cells grown on YNO-glucose medium for 10hrs and incubated with 
proteasome inhibitors (MG132 and Bortezomib) for 90 mins. Around 14 OD units of each strain were 
harvested by centrifugation. Immunoprecipit tion using GFP-Trap® _M beads was performed according to 
PDQXIDFWXUHU¶VSURWRFRO (Chromotek) with slight modifications. Cells were washed once with 1 mL cold 
lysis or RIPA buffer (50 mM Tris/Cl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100 
and 0.5% Deoxycholate) and resuspended in 0.75 mL of lysis EXIIHUFRQWDLQLQJȝJP/OHXSHSWLQDQG
mM PMSF (added just prior to use). Yeast cells were then lysed using glass beads (~ 30 mins) and samples 
were centrifuged at 8000 rpm at 4°C for 10 mins to remove cellular debris and unbroken cells. A fraction of 
supernatant (Load fraction) was collected and stored for SDS-PAGE analysis. The remaining supernatant 
fractions were then incubated with  ȝO GFP-Trap® _M beads (Chromotek) for 2 hrs at 4°C under 
constant mixing. The beads were magnetically separated until the supernatant was clear. The supernatant 
was discarded and beads were washed five times using 500 µl ice cold wash buffer (50 mM Tris/Cl pH 7.5, 
150 mM NaCl and 2 mM EDTA). The GFP-Trap® _M beads were then resuspended in 60 µl 4x SDS-
Sample buffer and boiled for 10 minutes at 95°C. Finally, the beads were separated magnetically and the 
supernatant (Elute fraction) was collected. The load and elute fractions were subjected to SDS-PAGE and 
immunoblotting with antibodies against GFP and Myc tagged epitope. 
 
ȕ- Oxidation assay 
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Yeast strains were grown on glucose medium containing 5 g/L D glucose, and 6.7 g/L YNB. When 
required; histidine, leucine, uracil, or methionine was added. To induce peroxisome proliferation cells were 
grown for at least 24 hours on 5 g/L glucose medium, and then transferred to YPO medium (1.07 g/L 
oleate, 2.16 g/L Tween-80, 5 g/L peptone, 3 g/L yeast extract, 25 mM potassium phosphate buffer (pH=6)). 
&HOOVZHUHJURZQRYHUQLJKWLQ<32PHGLXPWRLQGXFHȕ-R[LGDWLRQȕ-Oxidation assay in intact cells were 
performed as described previously by [80] with slight mRGLILFDWLRQV 7KH ȕ-oxidation capacity was 
measured in 50 mM MES, pH 6.0 and 9 g/L 1D&OVXSSOHPHQWHGZLWKȝ0-14C-oleate. Subsequently, 
14C-CO2 was trapped with 2 M NaOH and used to quantify the rate of fatty acid oxidation. Results are 
presented as percentages relative to the rate of oxidation of wild-type cells expressing Pxa1-mGFP (set to 
100). The data presented are from four independent experiments and significance is calculated using two-
WDLOHGVWXGHQW¶V W WHVW* represents P-values < 0.05, ** represents P-values < 0.01, and *** represents P-
values < 0.001. 
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Figure legends 
 
Figure 1: Pxa1MUT-mGFP targets to peroxisomes but displays reduced protein levels 
A. Pxa1-mGFP and Pxa1MUT-mGFP localization in cells co-expressing Pex3-mKate2 (row 4 and 6). Cells 
pre-cultivated on glucose were grown on oleate/glucose media to an OD600 of 1.5 and fluorescence 
images were taken. Here, a WT strain lacking fluorescent markers (row 1) together with WT strains 
expressing only Pex3-mKate2 (row 2), Pxa1-mGFP (row 3) or Pxa1MUT-mGFP (row 5) act as controls. 
Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluorescence. The 
line profiles (taken from the spots indicated with blue or yellow lines in images of WT.Pxa1-mGFP + 
Pex3-mKate2 and Pxa1MUT-mGFP + Pex3-mKate2 cells) indicate normalized fluorescent intensity 
along a line drawn through the peroxisomes (dotted yellow line). 6FDOHEDUȝP 
B. Cells expressing Pxa1-mGFP or Pxa1MUT-mGFP were grown on oleate/glucose media to an OD600 of 
1.5, lysed and samples were subjected to SDS-PAGE and immunoblotting with antibodies against 
mGFP and Pyc.  
C. Bar chart displaying Pxa1-mGFP and Pxa1MUT-mGFP levels, normalized to the loading control Pyc. 
Protein levels in Pxa1-mGFP cells were set to 1. Values represent the mean ± SD of three independent 
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experiments. Here, asterisks represent statistically significant decrease in Pxa1MUT-mGFP levels 
compared to Pxa1-mGFP levels. For quantification, blots in Figure S1C were used.  
 
Figure 2: Pxa1MUT-mGFP is rapidly degraded from peroxisomes 
A. Cycloheximide (CHX) chase analysis on cells expressing Pxa1-mGFP and Pxa1MUT-mGFP. (Left) Cells 
pre-cultivated on glucose media were grown on oleate/glucose media (inducing condition) to an OD600 
of 1.5. After treatment with DMSO (Ctrl) or CHX, cells were grown further on inducing medium and 
samples were collected at the indicated time points for immunoblotting with antibodies against mGFP 
and Pyc. (Right) Quantification of Pxa1-mGFP and Pxa1MUT-mGFP levels after CHX addition. Protein 
levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 
(set to 1). Values represent the mean ± SD of three independent experiments. For quantification, blots in 
Figure S1E were used.  
B. Co-localization analysis of Pxa1-mGFP (Left) and Pxa1MUT-mGFP (Right) with the peroxisomal marker 
Pex3-mKate2 after CHX treatment. Cells expressing Pxa1-mGFP or Pxa1MUT-mGFP together with 
Pex3-mKate2 were grown on oleate/glucose media to an OD600 of 1.5 and treated with CHX. 
Fluorescence images were taken from cells grown on oleate/glucose media at the indicated time points 
(mins) after CHX addition. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- 
EDFNJURXQGIOXRUHVFHQFH6FDOHEDUȝP. Line profiles were generated as described in Figure 1.  
C. Box plot quantification of mGFP and mKate2 fluorescence intensity at the peroxisomal membrane in 
WT cells producing Pex3-mKate2 and Pxa1-mGFP (Left) or Pxa1MUT-mGFP (Right) after CHX 
treatment. Fluorescence intensities were measured in cells (n=40) using ImageJ as described in the 
materials and methods section. The box represents intensity values from the 25th  percentile to the 75th  
percentile. The orange area represents intensity values from the 25th  -50th  percentile and the grey area 
represents intensity values from the 50th -75th  percentile. Whiskers indicate maximum and minimum 
values. 
D. Average ratio ± SD per cell (n = 40) of mGFP to mKate intensities in WT cells producing Pex3-mKate2 
and Pxa1-mGFP (Left) or Pxa1MUT-mGFP (Right). Numbers above the columns (Left) depict the p-
value. Asterisks (Right) denote significance between ratios at different time points, ** P <0.01- 
statistically significant (Right) and P> 0.05- not significant (Left). 
 
Figure 3: Inhibiting the proteasome but not autophagy disturbs Pxa1MUT-mGFP degradation  
A. Graph representing Pxa1MUT-mGFP levels in pdr5 cells under proteasome inhibitor (PI) conditions. 
pdr5 cells expressing Pxa1MUT-mGFP pre-cultivated on glucose were grown on oleate/glucose media 
for 10 h. After incubation with DMSO or proteasome inhibitors (MG132 and Bortezomib) for 90 mins, 
CHX was added to DMSO (represented as CHX) and PI treated cells (denoted as 
CHX+MG132+Bortezomib. TCA samples for western blotting were collected from cells grown on 
oleate/glucose media at the indicated time points after treatment with inhibitors. Protein levels were 
normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). 
Values represent the mean ± SD of three independent experiments. For quantification, blots in Figure 
S1F were used.  
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B. Pxa1MUT-mGFP levels in WT and atg12 cells after CHX treatment. Cells pre-cultivated on glucose were 
grown on oleate/glucose media to an OD600 of 1.5 and treated with CHX. TCA samples were collected 
from cells grown on oleate/glucose at the indicated time points after CHX treatment and probed with 
western blotting. Protein levels were normalized to Pyc at the corresponding time point and to the 
protein levels at time point 0 (set to 1). For quantification, blots in Figure S1G were used.  
C. Quantification of Pxa1MUT-mGFP levels in WT cells and cells expressing Myc-tagged ubiquitin (Ub) or 
ubiquitin mutant (UbK48R) after treatment with CHX. The experiment and quantification of levels were 
performed as mentioned in Figure 3B. Values represent the mean ± SD of three independent 
experiments. For quantification, blots in Figure S1G were used. 
D. Immunoprecipitation performed using anti-GFP antibodies on lysates from pdr5 cells, pdr5.Pxa1MUT-
mGFP cells, pdr5.Pxa1MUT-mGFP/MycUb cells and pdr5.MycUb cells. Cells were pre-cultivated on 
glucose, transferred to oleate/glucose media for 10 hrs and incubated with proteasome inhibitors 
(MG132 and Bortezomib) for 90 mins. Pxa1MUT-mGFP was immunoprecipitated under native 
conditions using GFP-trap magnetic beads. Load and elute fractions were subjected to immunoblotting 
with antibodies against the Myc-tag (to detect Myc-ubiquitin) or the GFP-tag (to detect Pxa1MUT-
mGFP). 
 
Figure 4: Identifying factors involved in Pxa1MUT-tFT degradation by tandem fluorescent timer  
A. Schematic representation of the Pxa1-tandem fluorescent timer (tFT) fusion. Pxa1p is fused to two 
fluorescent proteins with different maturation kinetics: rapidly maturing sfGFP and slow maturing 
mCherry. The fluorescent intensity ratio of mCherry to sfGFP provides information of Pxa1p stability. 
B. WT cells together with cells expressing Pxa1-mGFP, Pxa1-tFT or Pxa1MUT-mGFP were initially grown 
on glucose, shifted to oleate/glucose media and grown until an OD600 of 1.5. After lysis, samples were 
probed by immunoblotting with antibodies against mGFP and Pyc. *denotes a shorter, mCherry-sfGFP 
product resulting from mCherry hydrolysis during TCA treatment [42, 81] and ** denotes a tFT 
fragment produced by incomplete proteasomal processing [42]. 
C. The stability of tFT tagged Pxa1p and Pex11p was assayed using CHX chase analysis. Cells pre-
cultivated on glucose were grown on oleate/glucose media an OD600- 1.5. After treatment with CHX, 
cells were further grown on oleate/glucose media and samples collected at the indicated points were 
subjected for western blotting. Protein levels obtained at each time point were normalized to Pyc at the 
corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean ± 
SD of three independent experiments. For quantification, blots in Figure S1H were used. 
D. Screen for components involved in Pxa1-tFT stability. WT and mutant cells expressing Pxa1-tFT were 
grown on oleate/glucose plates and fluorescent intensities were measured. The resulting mCherry/sfGFP 
ratio on the indicated days (1-3) were used to calculate the Z-score (see materials and methods). Z-score 
colour coded from blue (decrease) to red (increase), represents changes in Pxa1-tFT stability. Mutant 
strains with Z-score >1.0 (indicated by *) on two of the three days tested were defined as potentially 
interesting.   
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E. Western blot analysis of Pxa1-tFT levels in WT, atg12, pex2 and pex4 cells grown on oleate/glucose 
media to an OD600 of 1.5. After lysis, samples were probed by immunoblotting with antibodies against 
mGFP and Pyc. *denotes a shorter, mCherry-sfGFP product resulting from mCherry hydrolysis during 
TCA lysate preparation [42]. The apparent discrepancy between the molecular weight of Pxa1-tFT in 
this panel and in Figure 4B is because samples here were run onto a 7.5% acrylamide SDS-PAGE gel 
while samples in 4B were loaded onto a 10% acrylamide SDS-PAGE gel, resulting in a different run 
profile. 
 
Figure 5: Pxa1MUT-mGFP degradation is inhibited in peroxisome deficient strains  
A. Bar chart displaying Pxa1MUT-mGFP levels in WT, pex2 and pex4 strains (Left) and WT, atg12 and 
pex5 strains (Right). Cells pre-cultivated on glucose were grown on oleate/glucose to an OD600 of ~1.5 
and TCA samples were collected for western blotting. For quantification of Pxa1MUT-mGFP levels, blots 
in Figure S2A were used. Pxa1MUT-mGFP levels in WT were set to 1, values represent the mean ± SD 
of three independent experiments. Asterisks represent statistically significant increase of Pxa1MUT-
mGFP levels in mutant strains compared to in WT cells. ** P <0.01- statistically significant and P> 
0.05- not significant (NS). 
B. CHX chase of Pxa1MUT-mGFP in WT, pex2 and pex4 strains (Top) and WT, atg12 and pex5 strains 
(Bottom). Cells were grown on oleate/glucose media to an OD600 of 1.5, treated with CHX and samples 
were collected from oleate/glucose grown cells at the indicated time points after CHX treatment. Protein 
levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 
(set to 1). Values represent the mean ± SD of three independent experiments. For quantification, blots in 
Figure S2B were used.  
C. Co-localization analysis of Pxa1MUT-mGFP with the peroxisomal marker Pex3-mKate2 in WT, pex2, 
pex4 and pex5 cells. The WT strain lacking fluorescent markers was used as control. Fluorescence 
images were taken from cells grown on oleate/glucose media to an OD600 of 1.5. Blue arrows- GFP 
spots, yellow arrows- mKate2 spots and red arrows- EDFNJURXQGIOXRUHVFHQFH6FDOHEDUȝP 
 
Figure 6: Ufd4, a cytosolic E3 ligase is involved in Pxa1MUT-mGFP degradation   
A. Pxa1MUT-mGFP levels in WT, ufd4, nam7, ela1, dsk2, skp1, tul1 or dma2 cells. TCA samples for 
western blotting were collected from cells pre-cultivated on glucose and grown on oleate/glucose to an 
OD600 of ~1.5. For quantification of Pxa1MUT-mGFP levels, blots in Figure S2A were used. Pxa1MUT-
mGFP levels in WT were set to 1, values represent the mean ± SD of three independent experiments. 
Numbers above the columns depict the p-value. 
B. Ten-fold serial dilutions of WT and pex4 cells together with WT and ufd4 cells producing Pxa1MUT- 
mGFP were spotted on oleate plates and grown at 30º C for 7 days.  
C. CHX chase of Pxa1MUT-mGFP in WT and ufd4 strains. Cells were pre-cultivated on glucose, grown on 
oleate/glucose to an OD600 1.5, treated with CHX and samples were collected from oleate/glucose 
grown cells at the indicated time points after CHX addition. Protein levels were normalized to Pyc at the 
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corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean ± 
SD of three independent experiments. For quantification, blots in Figure S2B were used. 
D. Co-localization analysis of Pxa1MUT-mGFP with the peroxisomal marker Pex3-mKate2 in ufd4 (Top 
panel) or WT (Bottom panel, taken from Figure 2A, for comparison) cells, after CHX treatment. Cells 
were grown as indicated in Figure 6C and images were taken from cells grown on oleate/glucose media 
at the indicated time points (mins) after CHX treatment. Blue arrows- GFP spots, yellow arrows- 
mKate2 spots and red arrows- background fluorescence6FDOHEDUȝP. Line profiles were generated 
as described in Figure 1. The circular structures visible in GFP images of ufd4.Pxa1MUT-mGFP cells 
(top panel) expressing Pxa1MUT-mGFP can also be seen in images of WT.Pxa1MUT-mGFP cells (Figure 
S1B, top lane) and likely represent large peroxisomes.  
 
Figure 7: Inhibiting Pxa1MUT-mGFP degradation enhances ȕ-oxidation activity in vivo.  
A. Bar chart displaying ȕ-oxidation activity in WT and ufd4 cells expressing Pxa1-mGFP or Pxa1MUT-
mGFP. ȕ-oxidation activity was measured in cells grown overnight on oleate/glucose media. ȕ-
oxidation in pxa1 and fox1 cells acts as control. The activity in WT.Pxa1-mGFP cells was taken as a 
reference [100%]. Values represent the mean ± SD of four independent experiments. Numbers above 
the columns depict the p-value calculated to determine whether changes to ȕ±oxidation activity in the 
different strains, are significant. 
B. Bar chart displaying Pxa1-mGFP and Pxa1MUT-mGFP levels in WT and ufd4 cells. Pex14p levels in WT 
and ufd4 cells acts as a control. Cells pre-cultivated on glucose were grown on oleate/glucose to an 
OD600 of 1.5, cells were lysed and samples were probed by immunoblotting. For quantification, blots in 
Figure S2C were used. Pxa1-mGFP levels in WT.Pxa1-mGFP cells were set to 1. Similarly, Pex14 
levels in WT.Pxa1-mGFP cells were used as a reference and set to 1. Values represent the mean ± SD of 
three independent experiments. Numbers above the columns depict the p-value calculated to determine 
whether changes to Pxa1/Pxa1MUT-mGFP or Pex14p levels in the different strains, when compared to 
the corresponding WT strain, are significant. 
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Tables 
 
Table 1. Yeast strains used in this study 
Strain Description [genotype] Reference 
BY4741  DdĂŚŝƐ ?ȴ ?ůĞƵ ?ȴ ?ŵĞƚ ? ?ȴ ?ƵƌĂ ?ȴ ? [1] (Knop lab) 
BJ1991 MATa, leu2, trp1, ura3-251, prb1-1122, pep4-3, gal2 [2]  
yMaM330 [Wild 
type- WT] 
DdĂůƉŚĂŚŝƐ ?ȴ ?ůĞƵ ?ȴ ?ŵĞƚ ? ?ȴ ?ƵƌĂ ?ȴ ?ĐĂŶ ?ȴ ? ?
STE2pr-ƐƉ,/^ ?ůǇƉ ?ȴ ? ?^d ?Ɖƌ->h ?ůĞƵ ?ȴ ? ?'> ?Ɖƌ- I-
SCEI-natNT2                              
[1]  (Knop lab) 
WT.PEX3-mKate2 yMaM330, PEX3::mKate2-hphMX This study (Figure 1) 
WT.PXA1-mGFP yMaM330, PXA1::mGFP-bleMX6 This study (Figure 1, 2, 4, 
7, S1 and S2) 
WT.PXA1
MUT
-mGFP yMaM330 , PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 1, 2, 3, 
4, 5, 6, 7, S1 and S2) 
WT. PXA1
MUT
-mGFP 
+ PEX3-mKate2 
yMaM330, WT. PXA1
MUT
-mGFP + PEX3::mKate2-
hphMX 
This study (Figure 1) 
WT. PXA1-mGFP + 
PEX3-mKate2 
yMaM330, WT. PXA1-mGFP + PEX3::mKate2-hphMX This study (Figure 1 and 
Figure 2) 
WT. PXA1
MUT
-mGFP 
+ DsRed-SKL 
yMaM330, WT. PXA1
MUT
-mGFP + SKL::DsRed-hphMX This study (Figure S1) 
PXA1-tFT yMaM330, PXA1::mCherry-I-SceIsite-SpCYC1term-
ScURA3-I-SceIsite-ŵŚĞƌƌǇȴE-sfGFP 
This study (Figure 4 and 
S1H) 
PEX11-tFT yMaM330, PEX11::mCherry-I-SceIsite-SpCYC1term-
ScURA3-I-SceIsite-ŵŚĞƌƌǇȴE-sfGFP 
Knop lab (Figure 4 and 
S1H) 
UPS deletion library BY4741, goi deletions::kanMX [1] 
yMaM344 yMaD ? ? ? ?ƵƌĂ ?ȴ ? ? ?ŵŚĞƌƌǇA?E-I-SceIsite-
SpCYC1term-ScURA3-I-SceIsite-ŵŚĞƌƌǇA?E 
[1] 
atg12 atg12 deletion strain, BY4741, atg12::kanMX Knop lab 
pex2 pex2 deletion strain, BY4741, pex2::kanMX Knop lab 
pex4 pex4 deletion strain, BY4741, pex4::kanMX Knop lab 
ufd4 ufd4 deletion strain, BY4741, ufd4::kanMX Knop lab 
pdr5 pdr5 deletion strain, BY4741, pdr5::kanMX Knop lab 
nam7 nam7 deletion strain, BY4741, nam7::kanMX Knop lab 
ela1 ela1 deletion strain, BY4741, ela1::kanMX Knop lab 
dsk2 dsk2 deletion strain, BY4741, dsk2::kanMX Knop lab 
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skp2 skp2 deletion strain, BY4741, skp2::kanMX Knop lab 
dma2 dma2 deletion strain, BY4741, dma2::kanMX Knop lab 
tul1 tul1 deletion strain, BY4741, tul1::kanMX Knop lab 
atg12.PXA1-tFT  yMaM330, PXA1-tFT + atg12::kanMX This study (Figure 4) 
pex2.PXA1-tFT  yMaM330, PXA1-tFT + pex2::kanMX This study (Figure 4) 
pex4.PXA1-tFT  yMaM330, PXA1-tFT + pex4::kanMX This study (Figure 4) 
pdr5.PXA1
MUT
-mGFP BY4741, pdr5 + PXA1G650S/K651R:: mGFP-bleMX6 This study (Figure 2 and 
S1) 
atg12.PXA1
MUT
-
mGFP 
BY4741, atg12 + PXA1G650S/K651R:: mGFP-bleMX6 This study (Figure 2, 4, S1 
and S2) 
pex2.PXA1
MUT
-mGFP YMaM330, WT. PXA1
MUT
-mGFP + pex2 deletion 
pex2::kanMX 
This study (Figure 5 and 
S2) 
pex2.PXA1
MUT
-mGFP 
+ PEX3-mKate2 
yMaM330, pex2 PXA1
MUT
-mGFP + PEX3::mKate2-
hphMX 
This study (Figure 5) 
pex4.PXA1
MUT
-mGFP YMaM330, WT. PXA1
MUT
-mGFP + pex4 deletion 
pex4::kanMX 
This study (Figure 5 and 
S2) 
pex4.PXA1
MUT
-mGFP 
+ PEX3-mKate2 
yMaM330, pex4 PXA1
MUT
-mGFP + PEX3::mKate2-
hphMX 
This study (Figure 5) 
pex5.PXA1
MUT
-mGFP YMaM330, WT. PXA1
MUT
-mGFP + pex5 deletion 
pex5::kanMX 
This study (Figure 5 and 
S2) 
pex5.PXA1
MUT
-mGFP 
+ PEX3-mKate2 
yMaM330, pex5 PXA1
MUT
-mGFP + PEX3::mKate2-
hphMX 
This study (Figure 5) 
ufd4.PXA1
MUT
-mGFP BY4741, ufd4 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6, 7 
and S2) 
ufd4.PXA1
MUT
-mGFP 
+ PEX3-mKate2 
ufd4 PXA1
MUT
-mGFP + PEX3::mKate2-hphMX This study (Figure 6) 
nam7.PXA1
MUT
-
mGFP 
BY4741, nam7 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6) 
ela1.PXA1
MUT
-mGFP BY4741, ela1 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6) 
dsk2.PXA1
MUT
-mGFP BY4741, dsk2 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6) 
skp2.PXA1
MUT
-mGFP BY4741, skp2 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6) 
dma2.PXA1
MUT
-
mGFP 
BY4741, dma2 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6) 
tul1.PXA1
MUT
-mGFP BY4741, tul1 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figure 6) 
ufd4.PXA1
MUT
-mGFP 
+ DsRed-SKL 
ufd4 PXA1
MUT
-mGFP + SKL::DsRed-hphMX This study (Figure S1) 
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ufd4.PXA1-mGFP BY4741, ufd4 + PXA1::mGFP-bleMX6 This study (Figure 7 and 
S2) 
fox1 BJ1991, fox1::kanMX 
 
pxa1 yMaM330, pxa1 deletion , pxa1::hphMX This study (Figure 7) 
WT.PXA1
MUT
-
mGFP+MycUb
K48R
 
yMaM330, WT PXA1
MUT
-mGFP + PCUP1-MycUbK48R 
[yeast episomal plasmid, YEP-Pcup1-MycUbK48R] 
This study (Figure 3 and 
S1) 
WT.PXA1
MUT
-mGFP+ 
MycUb 
WT PXA1
MUT
-mGFP + PCUP1-MycUb [yeast episomal 
plasmid, YEP-Pcup1-MycUb]  
This study (Figure 3 and 
S1) 
pdr5+ MycUb pdr5 +[yeast episomal plasmid, YEP-Pcup1-MycUb] This study (Figure 2 and 
S1) 
pdr5.PXA1
MUT
-mGFP 
+ MycUb 
pdr5.PXA1
MUT
-mGFP +[yeast episomal plasmid, YEP-
Pcup1-MycUb] 
This study (Figure 2 and 
S1) 
 
 
 
 
 
 
 
Table 2. Plasmids used in this study 
Plasmid Description Use Reference 
pGW053 YCplac111 plasmid containing 
PXA1 carrying two mutations 
G650S/K651R; LEU2, Amp
R
 
Amplification of C-terminal PXA1 
(with G650S/K651R)  
This study  
pHIPZ-mGFP 
fusinator 
pHIPZ containing mGFP; 
bleMX6, Amp
R
 
1. Vector for cloning  [3] 
2. C-terminal mGFP tagging to 
PXA1; genome integration 
pHIPZ-Pxa1
MUT
-
mGFP 
pHIPZ- mGFP containing C-
terminal PXA1 with two 
mutations G650S/K651R 
[PXA1
MUT
] ; bleMX6, Amp
R
 
C-terminal mGFP tagging to 
PXA1
MUT
; genome integration  
This study 
pHIPH-
Pex14mKate2 
pHIPH containing mKate2 and 
C-terminal of PEX14 ; hphMX, 
Amp
R
 
1. C-terminal mKate2 tagging to 
PEX3; genome integration 
[4] 
2. Gene disruption (pxa1) by 
hphMX marker  
pFA6a- kanMX6 pFA6a plasmid containing 
geneticin (kanMX6) resistance 
Gene disruption (atg12, pex2, 
pex4 and  pex5) by kanMX6 
[1]
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gene; kanMX, Amp
R 
 marker  
pMaM168 pFA6a plasmid containing tFT 
module (mCherry-I-SceIsite-
SpCYC1term-ScURA3-I-SceIsite-
ŵŚĞƌƌǇȴE-sfGFP) ; URA3, 
Amp
R
 
1. C-terminal tFT tagging ; PXA1-
tFT and PEX11-tFT integration 
into yMaM330 
[1]
 
pRG226 Yeast episomal plasmid (YEP) ; 
URA3 ? ?ʅŽƌŝ 
Vector for cloning  Addgene, 
64529 
pCGCN-FAA4 Plasmid containing CUP1 
promoter and mGFP; bleMX6, 
Amp
R
 
Amplification of CUP1 promoter; 
cloning 
[3]
 
pRDV1 Plasmid containing Myc tagged 
ubiquitin (Ub) under control of 
DHAS promoter; hphMX, Amp
R
 
Amplification of MycUb; vector 
for cloning  
[5] 
pRDV2 Plasmid containing Myc tagged 
ubiquitin mutant (UbK48R) 
under the control of DHAS 
promoter; hphMX, Amp
R
 
Amplification of MycUbK48R; 
Vector for cloning  
[5] 
YEP-PCUP1-MycUb Yeast episomal plasmid (YEP) 
containing CUP1promoter and 
MycUb; URA3, Amp
R
 
Integration into WT. PXA1
MUT
-
mGFP strain 
This study 
YEP-PCUP1-
MycUbK48R 
Yeast episomal plasmid (YEP) 
containing CUP1promoter and 
MycUbK48R; URA3, Amp
R
 
Integration into WT and WT. 
PXA1
MUT
-mGFP  
This study 
pHIPX7-
DsRedSKL 
Plasmid containing DsRed-SKL 
under the control of TEF 
promoter; LEU2, Amp
R
 
Vector for cloning [6] 
pHIPH7-DsRed-
SKL 
Plasmid containing DsRed-SKL 
under the control of TEF 
promoter; hphMX, kan
R
 
Vector for cloning This study 
pPTDH3-GFP-SKL Plasmid containing GFP-SKL 
under the control of TDH3 
promoter; LEU2, Amp
R
 
Amplification of TDH3 promoter; 
cloning 
[7] 
pHIPH8-
DsRedSKL 
Plasmid containing DsRed-SKL 
under the control of TDH3 
promoter, hphMX Amp
R
 
Integration into WT. PXA1
MUT
-
mGFP and   ufd4. PXA1
MUT
-mGFP 
strain 
This study 
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Highlights 
x Pxa1p is a yeast peroxisomal fatty acid transporter and homologue of human ALDP. 
x Mutations in ALDP cause the severe disease adrenoleukodystrophy.  
x A mutant form of Pxa1p (Pxa1MUT) is degraded by the proteasome system. 
x Ufd4p, a cytosolic E3 ligase, is involved in the degradation of peroxisomal Pxa1MUT. 
x Inhibition of Pxa1MUT degradation partially rescues Pxa1p activity in cells. 
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